Hormone replacement therapy and stroke: Are the results surprising?

Circulation

Volumn 103, Issue 5, 2001, Pages 620-622

  Tolbert, Todd ^a   Oparil, Suzanne ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Editorials; Hormones; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CONJUGATED ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEDROXYPROGESTERONE; WARFARIN;

CARDIOVASCULAR DISEASE; COMORBIDITY; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; LIFESTYLE; MORTALITY; NEUROPROTECTION; NONHUMAN; POSTMENOPAUSE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECONDARY PREVENTION; STROKE;

EID: 0035814742     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.5.620     Document Type: Review

References (26)

1. American Heart Association Prevention Conference IV: Prevention and rehabilitation of stroke: Risk factors
2. Residual disability in survivors of stroke: The Framingham Study
3. Blood pressure, stroke, and coronary heart disease, part 2: Short-term reductions in blood pressure: Overview of randomized drug trials in their epidemiological context
4. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the systolic hypertension in the elderly program (SHEP)
5. Prevention of a first stroke: A review of guidelines and a multidisciplinary consensus statement from the national stroke association
6. Decreased risk of stroke among postmenopausal hormone users: Results from a national cohort
7. Decreased mortality in users of estrogen replacement therapy
8. Hormone replacement therapy and the risk of stroke: Follow-up of a population-based cohort in Sweden
9. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
10. Postmenopausal hormone therapy and mortality
11. Hormonal replacement therapy morbidity and mortality in a prospective study of postmenopausal women
12. Postmenopausal hormone therapy and the risk of stroke: The heart and estrogen-progestin replacement study
13. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
14. Mechanisms of disease: The protective effects of estrogen on the cardiovascular system
15. Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat
16. Estradiol exerts neuroprotective effects when administered after ischemic insult
17. Stroke in estrogen receptor-a-deficient mice
18. Neuroprotection by estrogens in a mouse model of focal cerebral ischemia and in cultured neurons: Evidence for a receptor-independent antioxidative mechanism
19. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
20. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
21. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women
22. Hormone replacement therapy, inflammation, and hemostasis in elderly women
23. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study
24. The effect of hormone replacement therapy on blood pressure and cardiovascular risk factors in menopausal women with moderate hypertension
25. Design of the Women's Health Initiative clinical trial and observational study